Cell-cycle protein drives inflammation in aged cells

Senescent cells are cells that have stopped dividing but refuse to die. They release a cocktail of molecules that damage neighboring cells and sustain inflammation. This pattern is called the SASP (senescence-associated secretory phenotype) and is considered one of the key drivers of age-related disease.

The researchers, publishing in Nature Aging, found that the proteins cyclin D1 and CDK6 play a central role in the SASP. Both are known regulators of the cell cycle, but here they serve a different function. They activate the cGAS-STING signaling pathway, which detects DNA damage inside the cell and triggers an immune response. In senescent cells, this leads to sustained, low-grade inflammation.

An existing cancer drug blocks the process

The team then tested palbociclib, a drug already approved for breast cancer treatment that inhibits cyclin D1 and CDK6. In aged mice, palbociclib treatment produced a measurable reduction in inflammatory gene expression in senescent cells. Notably, motor function also improved and overall frailty declined.

These are animal studies, and it remains unclear whether palbociclib would produce the same effect in people outside of a cancer treatment context. Still, the finding points in an interesting direction. Repurposing existing drugs to counter aging is an approach researchers are taking increasingly seriously.

What this means for aging research

The study clarifies a mechanism that was not well understood. Cyclin D1 and CDK6 are not just relevant to cancer; they also help sustain the damage that senescent cells inflict over time. From a longevity standpoint, this is relevant: if this pathway can be suppressed with a well-tolerated existing drug, it could offer a new route to limit the effects of cellular aging. Clinical studies in humans are needed to confirm that.

Read the original article